The Immunohistochemistry Panel (3-IHC) at Lahore PCR Lab

Immunohistochemistry Panel (3-IHC) at Lahore PCR Lab

The Immunohistochemistry Panel (3-IHC) at Lahore PCR Lab is a highly specialized molecular pathology investigation designed to identify specific cellular proteins (antigens) within tissue samples. By utilizing laboratory-engineered antibodies that bind to target proteins, this diagnostic technique allows pathologists to visualize the precise distribution and localization of biomarkers under a microscope. The “3-IHC” designation refers to a targeted panel of three distinct immunohistochemical stains selected strategically based on the patient’s clinical presentation and preliminary histopathological findings. This specialized panel plays a critical role in modern oncology, pathology, and personalized medicine, offering diagnostic accuracy that standard Hematoxylin and Eosin (H&E) staining alone cannot achieve.

The fundamental mechanism of immunohistochemistry relies on the highly specific biochemical affinity between an antibody and its corresponding antigen. When a tissue biopsy or resection specimen is submitted to Lahore PCR Lab in Lahore, Pakistan, it undergoes meticulous processing to preserve cellular architecture. Ultra-thin sections of the tissue are exposed to three selected primary antibodies. If the target proteins are present in the tissue, the antibodies bind to them. A secondary detection system, typically conjugated with an enzyme like horseradish peroxidase (HRP), is then applied, followed by a chromogen substrate such as diaminobenzidine (DAB). This reaction produces a visible, colored precipitate at the site of antigen-antibody binding, which the pathologist can easily identify and quantify under a high-resolution light microscope.

The clinical importance of the 3-IHC panel lies in its ability to resolve complex diagnostic dilemmas. It is widely utilized to differentiate between benign and malignant lesions, determine the specific lineage of poorly differentiated tumors (such as distinguishing carcinomas from sarcomas or lymphomas), identify the primary site of metastatic cancers of unknown origin, and evaluate prognostic and therapeutic biomarkers. By analyzing three complementary markers simultaneously, pathologists at Lahore PCR Lab can construct a comprehensive molecular profile of the tissue, enabling oncologists to design highly targeted, effective, and individualized treatment regimens for patients in Lahore and across Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Because the Immunohistochemistry Panel (3-IHC) is performed on tissue specimens that have already been obtained via biopsy or surgical resection, there is no direct physical preparation required for the patient at the time of testing. However, to ensure accurate results, patients and referring physicians must follow these essential preparation guidelines:

• Submit the Paraffin Block: Provide the high-quality Formalin-Fixed Paraffin-Embedded (FFPE) tissue block containing the diagnostic tumor tissue.
• Provide H&E Slides: Submit the corresponding Hematoxylin and Eosin (H&E) stained glass slide from the primary diagnosis for correlation.
• Clinical Documentation: Include a detailed clinical history, previous pathology reports, relevant radiological findings, and the primary biopsy report.
• Specimen Integrity: Ensure the tissue was originally fixed in 10% neutral buffered formalin within the recommended cold ischemia time (ideally under 1 hour) and fixed for 6 to 48 hours.
• No Fasting Required: Since no direct blood draw or physical examination of the patient is conducted during this phase, fasting or medication adjustments are unnecessary.

During the Procedure

Once the tissue specimen is received at Lahore PCR Lab, it undergoes a highly standardized, quality-controlled analytical process:

• Specimen Verification: The laboratory staff verifies the patient’s identity, clinical history, and the integrity of the submitted paraffin block.
• Microtome Sectioning: A skilled histotechnologist cuts ultra-thin sections (approximately 3 to 4 micrometers thick) from the paraffin block using a precision microtome.
• Slide Mounting: The tissue sections are floated onto positively charged glass slides to ensure firm adhesion during subsequent staining steps.
• Deparaffinization and Rehydration: The slides are heated and treated with xylene and descending grades of alcohol to remove the paraffin wax and rehydrate the tissue.
• Antigen Retrieval: The tissue is subjected to Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions (citrate or EDTA) in a controlled heating chamber to unmask protein epitopes.
• Antibody Incubation: The slides are incubated with the three selected primary antibodies under optimized temperature and time conditions.
• Detection and Visualization: Secondary antibodies linked to enzyme complexes are applied, followed by a chromogen substrate to produce a visible color reaction.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin, dehydrated, cleared, and sealed with a coverslip for permanent preservation.
• Pathologist Interpretation: A consultant pathologist examines the slides under a microscope to evaluate the staining intensity, pattern (nuclear, cytoplasmic, or membranous), and percentage of positive cells.

When is an Immunohistochemistry Panel (3-IHC) Performed?

Differentiating Carcinoma, Sarcoma, and Lymphoma

When a patient presents with an undifferentiated or poorly differentiated tumor mass, standard microscopic evaluation may not clearly reveal the tissue of origin. Symptoms such as rapidly growing masses, unexplained weight loss, and localized pain prompt physicians to request a 3-IHC panel. By selecting three lineage-specific markers—such as Cytokeratin (for epithelial carcinomas), Vimentin (for mesenchymal sarcomas), and Leukocyte Common Antigen (for hematolymphoid malignancies)—pathologists can definitively classify the tumor’s histogenesis, which is critical because the therapeutic protocols for these cancers differ fundamentally.

Subtyping Breast Carcinomas for Targeted Therapy

In breast cancer management, identifying the molecular subtype of the tumor is essential for determining the prognosis and selecting systemic therapies. Patients presenting with breast lumps, abnormal mammograms, or nipple discharge undergo a biopsy. Physicians routinely order a targeted 3-IHC panel consisting of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2/neu). The results of this panel dictate whether the patient will benefit from hormone-blocking therapies, HER2-targeted monoclonal antibodies, or conventional chemotherapy.

Identifying the Primary Site in Metastatic Cancers of Unknown Primary

Metastatic disease of unknown primary (CUP) occurs when cancer cells have spread to secondary sites, such as the liver, lungs, or bones, without an obvious primary tumor source. Patients may present with generalized symptoms like bone pain, abdominal distension, or shortness of breath. To locate the primary malignancy, physicians request a 3-IHC panel utilizing organ-specific transcription factors and cytokeratins, such as CK7, CK20, and TTF-1 (for lung/thyroid) or CDX2 (for gastrointestinal tract), allowing for targeted local therapy rather than empirical treatment.

Distinguishing Benign Prostatic Lesions from Adenocarcinoma

Evaluating needle biopsies of the prostate can be challenging when lesions are extremely small or mimic benign conditions. Patients with elevated Prostate-Specific Antigen (PSA) levels or abnormal digital rectal exams undergo biopsies. Pathologists utilize a 3-IHC cocktail panel—typically containing AMACR (an oncogene overexpressed in cancer), p63, and High Molecular Weight Cytokeratin (which highlight the basal cell layer). The complete absence of the basal cell layer combined with AMACR positivity confirms a diagnosis of invasive prostatic adenocarcinoma.

Characterizing Lymphoproliferative Disorders and Lymphomas

Lymphoma diagnosis and classification require precise identification of the lymphocyte lineage. Patients presenting with painless lymphadenopathy, night sweats, and persistent fever are evaluated for lymphoproliferative disorders. A targeted 3-IHC panel using markers like CD20 (B-cell marker), CD3 (T-cell marker), and Ki-67 (proliferation index) or CD30 is requested by hematologists to accurately classify the lymphoma subtype according to the World Health Organization (WHO) guidelines, ensuring the selection of the correct immunochemotherapy regimen.

What Does an Immunohistochemistry Panel (3-IHC) Detect?

The Immunohistochemistry Panel (3-IHC) at Lahore PCR Lab is capable of detecting a wide array of specific cellular, nuclear, and cytoplasmic proteins. Depending on the clinical scenario and the specific panel selected, this test can detect:

• Estrogen Receptor (ER) Expression: Identifies hormone-sensitive cells in breast and gynecological tissues.
• Progesterone Receptor (PR) Expression: Assesses progesterone receptor status to predict response to endocrine therapy.
• HER2/neu Membrane Overexpression: Detects amplification of the HER2 oncogene in breast and gastric cancers.
• Ki-67 Proliferation Index: Measures the percentage of actively dividing tumor cells to assess tumor aggressiveness.
• Pan-Cytokeratin (Pan-CK): Confirms the epithelial origin of cells, establishing a diagnosis of carcinoma.
• Vimentin Positivity: Identifies mesenchymal cells, helping to diagnose sarcomas and melanomas.
• Leukocyte Common Antigen (LCA/CD45): Detects hematolymphoid cells, confirming lymphoma or leukemia.
• S100 Protein: Highlights neuroectodermal cells, useful in diagnosing melanoma and neural tumors.
• SOX10 Expression: A highly sensitive marker for melanoma and sustentacular cells in peripheral nerve sheath tumors.
• Thyroid Transcription Factor-1 (TTF-1): Detects primary adenocarcinomas of the lung and thyroid.
• Caudal-Type Homeobox 2 (CDX2): Identifies primary adenocarcinomas of the gastrointestinal tract, particularly colorectal cancer.
• Cytokeratin 7 (CK7): Helps differentiate primary sites; positive in lung, breast, and ovarian carcinomas.
• Cytokeratin 20 (CK20): Positive in transitional cell carcinomas and gastrointestinal tract adenocarcinomas.
• p63 Expression: Highlights basal cells in prostate and breast tissues, and confirms squamous cell differentiation.
• p40 Expression: A highly specific marker for squamous cell carcinoma of the lung and other sites.
• Synaptophysin: Detects neuroendocrine differentiation in tumors of the lung, pancreas, and gastrointestinal tract.
• Chromogranin A: Confirms neuroendocrine secretory granules within neoplastic cells.
• CD20 Expression: Identifies mature B-lymphocytes, crucial for subtyping B-cell lymphomas.
• CD3 Expression: Identifies T-lymphocytes, essential for subtyping T-cell lymphomas.
• AMACR (Alpha-Methylacyl-CoA Racemase): Overexpressed in prostatic adenocarcinoma cells.
• Desmin: Detects myogenic differentiation in smooth and skeletal muscle tumors.
• Myogenin: Confirms skeletal muscle differentiation, essential for diagnosing rhabdomyosarcoma.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely diagnostic reports are critical for initiating cancer therapies and making urgent clinical decisions. The turnaround time for an Immunohistochemistry Panel (3-IHC) is typically 5 to 7 working days. This timeframe is necessary to ensure meticulous tissue processing, precise antigen retrieval, optimal antibody incubation, and comprehensive review by our consultant pathologists. In complex cases requiring additional clinical correlation or decalcification, the reporting time may vary slightly to maintain the highest standards of diagnostic accuracy. Patients and healthcare providers can conveniently access reports online through the secure Lahore PCR Lab web portal, receive them via WhatsApp, or collect printed copies directly from our main facility in Lahore, Pakistan.

Immunohistochemistry Panel (3-IHC) Findings Overview

The following table outlines the common parameters evaluated in a 3-IHC panel, along with typical normal and abnormal findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Epithelial Markers (e.g., Pan-CK)	Negative in non-epithelial tissues (e.g., muscle, lymphoid tissue)	Strong cytoplasmic positivity in carcinomas, confirming epithelial lineage
Mesenchymal Markers (e.g., Vimentin)	Positive in normal stromal cells and connective tissues	Diffuse positivity in sarcomas, melanomas, or epithelial-mesenchymal transition (EMT)
Lymphoid Markers (e.g., LCA/CD45)	Positive only in normal circulating or tissue-resident inflammatory cells	Diffuse, intense positivity in lymphomas and lymphocytic leukemias
Breast Hormone Receptors (ER/PR)	Variable weak-to-moderate expression in normal breast lobular epithelium	Strong nuclear overexpression in luminal breast carcinomas; completely negative in triple-negative breast cancer
HER2/neu Protein Expression	Normal low-level membranous expression (Score 0 or 1+)	Strong, continuous circumferential membranous staining (Score 3+) indicating HER2 gene amplification
Proliferation Marker (Ki-67)	Low mitotic activity and proliferation index (typically less than 5% in normal tissues)	Elevated proliferation index (greater than 20% to 90%) indicating highly aggressive tumor growth
Neuroendocrine Markers (Synaptophysin/Chromogranin)	Negative in non-neuroendocrine tissues	Diffuse cytoplasmic positivity confirming neuroendocrine tumors, carcinoids, or small cell carcinomas
Prostate Basal Markers (p63/HMWCK)	Continuous, intact basal cell layer in benign prostatic glands	Complete loss of the basal cell layer, confirming invasive prostatic adenocarcinoma
Melanocytic Markers (S100/SOX10)	Negative in epithelial and lymphoid tissues	Strong nuclear and cytoplasmic positivity in malignant melanoma and neural crest tumors

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Immunohistochemistry Panel (3-IHC)?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with extensive expertise in oncopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort and clarity, providing dedicated support throughout the sample submission and reporting process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards, ensuring highly reproducible and reliable staining results.
• Professional Reporting: Our reports provide detailed semi-quantitative scoring, staining patterns, and clinical correlations to guide oncological decision-making.
• Modern Diagnostic Approach: We utilize advanced automated staining platforms and high-affinity antibodies to minimize background staining and false results.
• Comfortable Environment: Our main facility in Lahore, Pakistan, offers a welcoming and professional environment for patients submitting specimens.
• Convenient Location: Easily accessible location in Lahore, enabling efficient sample transport and timely processing.
• Commitment to Accurate Diagnosis: We are dedicated to delivering evidence-based, clinically precise diagnostic insights to support effective patient management.